Immunotherapies for Life

Press Releases

Clinical Pipeline Highlights

Product Candidate Target Load Indication/Treatment Development Phase

Pre-clinical

Phase I

Phase II

Phase III/
Registration
Naked Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)
Ongoing pivotal Phase II trial
Naked Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)
Ongoing Phase II trial
Naxitamab GD2 Naked (Front-Line) High-Risk Neuroblastoma (Pediatric)
Ongoing Phase II trial
Naked Relapsed (Second-Line) Osteosarcoma
Ongoing Phase II trial
Naked Chemoimmunotherapy for Relapsed/Refractory
High-Risk Neuroblastoma
Ongoing Phase I trial
131I CNS/Leptomeningeal Metastases from
Neuroblastoma (Pediatric)
Ongoing pivotal Phase II trial
Omburtamab B7-H3 131I Intrathecal Immunotherapy for CNS/Leptomeningeal Metastases
Ongoing Phase I trial
124I Diffuse Intrinsic Pontine Glioma (Pediatric)
Ongoing Phase I trial
131I Desmoplastic Small Round Cell Tumor (Pediatric)
Ongoing Phase I trial
Omburtamab-DTPA B7-H3 177Lu B7-H3 Positive CNS/Leptomeningeal Solid Tumors
huB7-H3 B7-H3 TBD Systemic Solid Tumors (Adult)
(Third-Line)
huGD2-BsAb GD2xCD3 Naked Refractory GD2-Positive Solid Tumors
Ongoing Phase I trial
huCD33-BsAb CD33xCD3 Naked Hematological Cancers Expressing CD33

Overview

Y-mAbs Therapeutics, Inc (Y-mAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. Y-mAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. Y-mAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Mission

Our Mission is to become the world leader in developing better and safer antibody based pediatric oncology products addressing clear unmet medical needs. We will expand into certain adult cancer indications and advance these in collaboration with partners.

Company Highlights

  • Y-mAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer
  • Memorial Sloan Kettering Cancer Center, the world’s largest and oldest private cancer institution, is Y-mAbs’ scientific collaboration partner and shareholder
  • From MSK, Y-mAbs has exclusive global rights to two clinical stage antibody programs with a strong validated clinical safety profile, treating more than 1,000 neuroblastoma patients. These programs are today used as “standard-of-care” treatment for patients at Memorial Sloan Kettering Cancer Center
  • Further, Y-mAbs has licensed a protein Multimerization Technology Platform – MULTI TAG™, incubated and developed at MSK to further enhance the therapeutic effect of antibodies
  • Several ongoing clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients
  • Y-mAbs has a management team with proven track record and antibody drug development experience as well as expertise in running leading public biopharmaceutical companies

Portal for Patients and Parents

X

Please insert contact information and specifics regarding diagnose to be contacted regarding treatment opportunities in Y-mAbs’ clinical trials

View Privacy
Statement
Send